Endurant Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Endurant Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,674	Closed	-$618K	–	63
2018 Q3	$618K	Buy	+3,674	New	+$632K	0.27%	60
2018 Q2	–	Sell	-5,100	Closed	-$770K	–	73
2018 Q1	$770K	Buy	5,100 +150	+3%	+$22K	0.29%	57
2017 Q4	$667K	Sell	4,950 -13,500	-73%	-$1.87M	0.2%	67
2017 Q3	$2.7M	Sell	18,450 -41,150	-69%	-$6.22M	0.82%	44
2017 Q2	$9.27M	Sell	59,600 -1,500	-2%	-$229K	2.62%	10
2017 Q1	$8.87M	Buy	61,100 +44,700	+273%	+$5.82M	2.85%	9
2016 Q4	$1.79M	Buy	+16,400	New	+$1.83M	0.74%	43
2015 Q4	–	Sell	-10,500	Closed	-$1.4M	–	82
2015 Q3	$1.4M	Sell	10,500 -500	-5%	-$86.1K	0.47%	53
2015 Q2	$1.94M	Buy	11,000 +300	+3%	+$53.9K	0.57%	50
2015 Q1	$1.85M	Buy	+10,700	New	+$1.84M	0.61%	54

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Endurant Capital Management's JAZZ Position: Q4 2018 in Review

Endurant Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 3,674 shares — an estimated $618K sold.

Endurant Capital Management first reported a position in JAZZ in Q1 2015 and held it in 10 quarters. The position peaked at $9.27M in Q2 2017. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

Endurant Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Endurant Capital Management sold 3,674 Jazz Pharmaceuticals shares in Q4 2018, an estimated $618K.
Endurant Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Endurant Capital Management's Jazz Pharmaceuticals position peaked at $9.27M in Q2 2017.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Endurant Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.